$1.82
+0.16 (+9.31%)
Open$1.78
Previous Close$1.67
Day High$1.85
Day Low$1.73
52W High$12.45
52W Low$9.35
Volume—
Avg Volume788.2K
Market Cap177.67M
P/E Ratio35.68
EPS$0.31
SectorBiotechnology
Analyst Ratings
Buy
20 analysts
Price Target
+603.8% upside
Current
$1.82
$1.82
Target
$12.81
$12.81
$8.62
$12.81 avg
$14.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.87M | 30.54M | 27.97M |
| Net Income | 5.42M | 4.38M | 4.75M |
| Profit Margin | 18.8% | 14.4% | 17.0% |
| EBITDA | 9.70M | 9.59M | 9.00M |
| Free Cash Flow | 5.96M | 5.15M | 6.45M |
| Rev Growth | -3.2% | +16.6% | +5.2% |
| Debt/Equity | 0.57 | 0.64 | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |